TS 011

Drug Profile

TS 011

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Neuroprotectants
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Stroke

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in Japan (Injection)
  • 30 Oct 2009 Pharmacodynamics data from animal studies in stroke presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top